Share-based Payment Arrangement, Expense in USD of MAXCYTE, INC. from 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
MAXCYTE, INC. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2019 to Q3 2025.
  • MAXCYTE, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1.95M, a 42% decline year-over-year.
  • MAXCYTE, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $11.6M, a 13.9% decline year-over-year.
  • MAXCYTE, INC. annual Share-based Payment Arrangement, Expense for 2024 was $13.1M, a 6.41% decline from 2023.
  • MAXCYTE, INC. annual Share-based Payment Arrangement, Expense for 2023 was $14M, a 19% increase from 2022.
  • MAXCYTE, INC. annual Share-based Payment Arrangement, Expense for 2022 was $11.8M, a 47.7% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

MAXCYTE, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $11.6M $1.95M -$1.42M -42% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025
Q2 2025 $13.1M $3.51M -$50K -1.4% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025
Q1 2025 $13.1M $3.04M +$24K +0.8% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025
Q4 2024 $13.1M $3.13M -$440K -12.3% 01 Oct 2024 31 Dec 2024 10-K 11 Mar 2025
Q3 2024 $13.5M $3.37M -$239K -6.62% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025
Q2 2024 $13.8M $3.56M +$45K +1.28% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025
Q1 2024 $13.7M $3.02M -$262K -8% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025
Q4 2023 $14M $3.57M +$456K +14.6% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025
Q3 2023 $13.5M $3.61M +$410K +12.8% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024
Q2 2023 $13.1M $3.52M +$546K +18.4% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024
Q1 2023 $12.6M $3.28M +$815K +33.1% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024
Q4 2022 $11.8M $3.12M +$670K +27.4% 01 Oct 2022 31 Dec 2022 10-K 12 Mar 2024
Q3 2022 $11.1M $3.2M +$913K +40% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 $10.2M $2.97M +$1.07M +56% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 $9.1M $2.46M +$1.14M +86.6% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023
Q4 2021 $7.96M $2.45M 01 Oct 2021 31 Dec 2021 10-K 15 Mar 2023
Q3 2021 $2.29M +$1.69M +282% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022
Q2 2021 $1.91M +$1.35M +241% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022
Q1 2021 $1.32M 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022
Q3 2020 $598K 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021
Q2 2020 $559K 01 Apr 2020 30 Jun 2020 10-Q 13 Sep 2021

MAXCYTE, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $13.1M -$896K -6.41% 01 Jan 2024 31 Dec 2024 10-K 11 Mar 2025
2023 $14M +$2.23M +19% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025
2022 $11.8M +$3.79M +47.7% 01 Jan 2022 31 Dec 2022 10-K 12 Mar 2024
2021 $7.96M +$5.49M +222% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2023
2020 $2.47M +$720K +41.1% 01 Jan 2020 31 Dec 2020 10-K 22 Mar 2022
2019 $1.75M 01 Jan 2019 31 Dec 2019 10-K 22 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.